{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:15:41Z","timestamp":1793301341156,"version":"4.5.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Blueprint Medicines Corporation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40257-025-00947-7","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T11:05:25Z","timestamp":1747739125000},"page":"499-510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Mastocytosis in the Skin: Approach to Diagnosis, Evaluation, and Management in Adult and Pediatric Patients"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5659-5734","authenticated-orcid":false,"given":"Lauren M.","family":"Madigan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan A.","family":"Boggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton V.","family":"Rets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro A.","family":"Gru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsewang","family":"Tashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Florell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody C.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"issue":"2","key":"947_CR1","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jmoldx.2010.10.004","volume":"13","author":"T Kristensen","year":"2011","unstructured":"Kristensen T, Vestergaard H, Moller MB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn. 2011;13(2):180\u20138.","journal-title":"J Mol Diagn"},{"issue":"4","key":"947_CR2","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/bjh.12916","volume":"166","author":"SS Cohen","year":"2014","unstructured":"Cohen SS, Skovbo S, Vetergaard H, et al. Epidemiology of systemic mastocytosis in Denmark. Br J Haematol. 2014;166(4):521\u20138.","journal-title":"Br J Haematol"},{"issue":"1","key":"947_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jaci.2004.02.045","volume":"114","author":"P Valent","year":"2004","unstructured":"Valent P, Sperr WR, Schwartz LB, et al. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol. 2004;114(1):3\u201311.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"947_CR4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.iac.2014.01.003","volume":"34","author":"K Brockow","year":"2014","unstructured":"Brockow K. Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin North Am. 2014;34(2):283\u201395.","journal-title":"Immunol Allergy Clin North Am"},{"key":"947_CR5","unstructured":"Carter MC, Metcalfe DD. Mastocytosis. In: Young NS, Gerson SL, Hight KH, editors. Clinical hematology. Philadelphia (PA): Mosby, Inc.; 2006."},{"issue":"4","key":"947_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1046\/j.1525-1470.2001.01939.x","volume":"18","author":"A Chang","year":"2001","unstructured":"Chang A, Tung RC, Schlesinger T, et al. Familial cutaneous mastocytosis. Pediatr Dermatol. 2001;18(4):271\u20136.","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"947_CR7","first-page":"320","volume":"7","author":"D Ben-Amitai","year":"2005","unstructured":"Ben-Amitai D, Metzker A, Cohen HA. Pediatric cutaneous mastocytosis: a review of 180 patients. Isr Med Assoc J. 2005;7(5):320\u20132.","journal-title":"Isr Med Assoc J"},{"issue":"3","key":"947_CR8","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/jid.2009.281","volume":"130","author":"C Bodemer","year":"2010","unstructured":"Bodemer C, Hermine O, Palmerini F, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol. 2010;130(3):804\u201315.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"947_CR9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","volume":"37","author":"P Valent","year":"2007","unstructured":"Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37(6):435\u201353.","journal-title":"Eur J Clin Invest"},{"issue":"11","key":"947_CR10","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200\u201328.","journal-title":"Blood"},{"issue":"7","key":"947_CR11","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36(7):1703\u201319.","journal-title":"Leukemia"},{"issue":"4","key":"947_CR12","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.iac.2023.04.011","volume":"43","author":"P Valent","year":"2023","unstructured":"Valent P, Sotlar K, Horny HP, et al. World Health Organization classification and diagnosis of mastocytosis: update 2023 and future perspectives. Immunol Allergy Clin North Am. 2023;43(4):627\u201349.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"11","key":"947_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000646","volume":"5","author":"P Valent","year":"2021","unstructured":"Valent P, Akin C, Hartmann K, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. Hemasphere. 2021;5(11): e646.","journal-title":"Hemasphere."},{"key":"947_CR14","unstructured":"NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) for systemic mastocytosis V.3.2024. \u00a9 National Comprehensive Cancer Network, Inc. 2024. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1490. Accessed 12 Sep 2024."},{"issue":"13","key":"947_CR15","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","volume":"102","author":"HC Kluin-Nelemans","year":"2003","unstructured":"Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood. 2003;102(13):4270\u20136.","journal-title":"Blood"},{"issue":"1","key":"947_CR16","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1182\/blood-2009-10-249979","volume":"115","author":"A Pardanani","year":"2010","unstructured":"Pardanani A, Lim, KH, Lasho TL, et al. WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. Blood. 2010;115(1):150\u20131.","journal-title":"Blood"},{"issue":"1","key":"947_CR17","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jaci.2015.05.008","volume":"137","author":"I Alvarez-Twose","year":"2016","unstructured":"Alvarez-Twose I, Jara-Acevedo M, Morgado JM, et al. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. J Allergy Clin Immunol. 2016;137(1):168\u201378.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"947_CR18","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1001\/jama.1965.03090230045010","volume":"194","author":"RM Caplan","year":"1965","unstructured":"Caplan RM. Urticaria pigmentosa and systemic mastocytosis. JAMA. 1965;194(10):1077\u201380.","journal-title":"JAMA"},{"key":"947_CR19","first-page":"359","volume":"43","author":"ALCG Sezary","year":"1936","unstructured":"Sezary ALCG, Chauvillon P. Dermographisme et mastocytose. Bull Soc Fr Dermatol Syph. 1936;43:359\u201361.","journal-title":"Bull Soc Fr Dermatol Syph"},{"issue":"1","key":"947_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","volume":"137","author":"K Hartmann","year":"2016","unstructured":"Hartmann K, Escribano L, Grattan C, et al. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016;137(1):35\u201345.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"947_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jdcr.2016.11.004","volume":"3","author":"M Herrero-Moyano","year":"2017","unstructured":"Herrero-Moyano M, Capusan TM, Perez-Plaza A, et al. Intertriginous maculopapular mastocytosis in a patient with acute myeloid leukemia. JAAD Case Rep. 2017;3(1):61\u20133.","journal-title":"JAAD Case Rep."},{"issue":"7","key":"947_CR22","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/ijd.14166","volume":"58","author":"BJ Simmons","year":"2019","unstructured":"Simmons BJ, LeBlanc RE, Glass JS. Intertriginous mastocytosis: a rare presentation of an uncommon disease. Int J Dermatol. 2019;58(7):852\u20133.","journal-title":"Int J Dermatol"},{"issue":"4","key":"947_CR23","doi-asserted-by":"publisher","first-page":"E79","DOI":"10.1111\/ijd.14385","volume":"58","author":"J Sammut","year":"2019","unstructured":"Sammut J, Mercieca L, Boffa MM, et al. Palmoplantar maculopapular cutaneous mastocytosis. Int J Dermatol. 2019;58(4):E79-80.","journal-title":"Int J Dermatol"},{"issue":"1","key":"947_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1365-2230.2008.02931.x","volume":"34","author":"EJ Soilleux","year":"2009","unstructured":"Soilleux EJ, Brown VL, Bowling J. Cutaneous mastocytosis localized to a radiotherapy field. Clin Exp Dermatol. 2009;34(1):111\u20132.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"947_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1365-2133.1975.tb06482.x","volume":"93","author":"WA Griffiths","year":"1975","unstructured":"Griffiths WA, Daneshbod K. Pseudoxanthomatous mastocytosis. Br J Dermatol. 1975;93(1):91\u20135.","journal-title":"Br J Dermatol"},{"issue":"4","key":"947_CR26","doi-asserted-by":"publisher","first-page":"468","DOI":"10.4103\/0019-5154.185751","volume":"61","author":"NS Nabavi","year":"2016","unstructured":"Nabavi NS, Nejad MH, Feli S, et al. Adult onset of xanthelasmoid mastocytosis: report of a rare entity. Indian J Dermatol. 2016;61(4):468.","journal-title":"Indian J Dermatol"},{"issue":"2","key":"947_CR27","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1525-1470.1991.tb00307.x","volume":"8","author":"A Revert","year":"1991","unstructured":"Revert A, Jorda E, Ramon D, et al. Xanthelasmoid mastocytosis. Pediatr Dermatol. 1991;8(2):152\u20134.","journal-title":"Pediatr Dermatol"},{"issue":"7","key":"947_CR28","doi-asserted-by":"publisher","first-page":"13030","DOI":"10.5070\/D3217028113","volume":"21","author":"MV Hoang","year":"2015","unstructured":"Hoang MV, Van Dang P, Van Bui D, et al. Acquired cutis laxa associated with cutaneous mastocytosis. Dermatol Online J. 2015;21(7):13030.","journal-title":"Dermatol Online J"},{"issue":"4","key":"947_CR29","doi-asserted-by":"publisher","first-page":"566","DOI":"10.4103\/0377-4929.107824","volume":"55","author":"D Mutreja","year":"2012","unstructured":"Mutreja D, Purohit A, Singh PK, et al. A 60-year-old lady with leonine facies: a rare diagnosis. Indian J Pathol Microbiol. 2012;55(4):566\u20138.","journal-title":"Indian J Pathol Microbiol"},{"issue":"1","key":"947_CR30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.2174\/1573396315666181120163952","volume":"15","author":"AKC Leung","year":"2019","unstructured":"Leung AKC, Lam JM, Leong KF. Childhood solitary cutaneous mastocytoma: clinical manifestations, diagnosis, evaluation, and management. Curr Pediatr Rev. 2019;15(1):42\u20136.","journal-title":"Curr Pediatr Rev"},{"issue":"12","key":"947_CR31","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1111\/j.1468-3083.2011.04350.x","volume":"26","author":"M Lange","year":"2012","unstructured":"Lange M, Niedoszytko M, Nedoszytko B, et al. Diffuse cutaneous mastocytosis: analysis of 10 cases and a brief review of the literature. J Eur Acad Dermatol Venereol. 2012;26(12):1565\u201371.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"947_CR32","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/pbc.22125","volume":"53","author":"A Uzzaman","year":"2009","unstructured":"Uzzaman A, Maric I, Noel P, et al. Pediatric-onset mastocytosis: a long term clinical follow-up and correlation with bone marrow histopathology. Pediatr Blood Cancer. 2009;53(4):629\u201334.","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"947_CR33","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.jaci.2015.05.034","volume":"136","author":"T Wiechers","year":"2015","unstructured":"Wiechers T, Rabenhorst A, Schick T, et al. Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis. J Allergy Clin Immunol. 2015;136(6):1581-90.e3.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"947_CR34","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.iac.2018.04.001","volume":"38","author":"A Matito","year":"2018","unstructured":"Matito A, Azana JM, Torrelo A, et al. Cutaneous mastocytosis in adults and children: new classification and prognostic factors. Immunol Allergy Clin North Am. 2018;38(3):351\u201363.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"4","key":"947_CR35","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1067\/mjd.2003.98","volume":"48","author":"K Brockow","year":"2003","unstructured":"Brockow K, Akin C, Huber M, et al. Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology. J Am Acad Dermatol. 2003;48(4):508\u201316.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"947_CR36","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1111\/jdv.17563","volume":"35","author":"K Brockow","year":"2021","unstructured":"Brockow K. Unsatisfactory agreement using current classification of maculopapular cutaneous mastocytosis. J Eur Acad Dermatol Venereol. 2021;35(10):1917\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"947_CR37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaip.2013.09.004","volume":"2","author":"S Jennings","year":"2014","unstructured":"Jennings S, Russell N, Jennings B, et al. The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions. J Allergy Clin Immunol Pract. 2014;2(1):70\u20136.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"947_CR38","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/j.jaip.2022.05.037","volume":"10","author":"P Pyatilova","year":"2022","unstructured":"Pyatilova P, Akin C, Alvarez-Twose I, et al. Refined treatment response criteria for indolent systemic mastocytosis proposed by the ECNM-AIM Consortium. J Allergy Clin Immunol Pract. 2022;10(8):2015\u201324.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"947_CR39","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1111\/all.12920","volume":"71","author":"B van Anrooij","year":"2016","unstructured":"van Anrooij B, Kluin-Nelemans JC, Safy M, et al. Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis. Allergy. 2016;71(11):1585\u201393.","journal-title":"Allergy"},{"issue":"6","key":"947_CR40","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.jaci.2010.02.019","volume":"125","author":"I Alvarez-Twose","year":"2010","unstructured":"Alvarez-Twose I, de Olano DG, Sanchez-Munoz L, et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol. 2010;125(6):1269-78.e2.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"947_CR41","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","volume":"63","author":"K Brockow","year":"2008","unstructured":"Brockow K, Jofer C, Behrendt H, et al. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy. 2008;63(2):226\u201332.","journal-title":"Allergy"},{"issue":"5","key":"947_CR42","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.3390\/ijms22052684","volume":"22","author":"K Brockow","year":"2021","unstructured":"Brockow K, Plata-Nazar K, Lange M, et al. Mediator-related symptoms and anaphylaxis in children with mastocytosis. Int J Mol Sci. 2021;22(5):2684.","journal-title":"Int J Mol Sci"},{"key":"947_CR43","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.bone.2017.09.005","volume":"105","author":"Y Degboe","year":"2017","unstructured":"Degboe Y, Eischen M, Nigon D, et al. Prevalence and risk factors for fragility fracture in systemic mastocytosis. Bone. 2017;105:219\u201325.","journal-title":"Bone"},{"issue":"12","key":"947_CR44","doi-asserted-by":"publisher","first-page":"4459","DOI":"10.1016\/j.jaip.2021.08.001","volume":"9","author":"A Makovoz","year":"2021","unstructured":"Makovoz A, Wang J, Oshegbo G, et al. Assessment of osteoporosis and fracture risk in mastocytosis within a North American cohort. J Allergy Clin Immunol Pract. 2021;9(12):4459-67.e10.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"947_CR45","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/j.1398-9995.2011.02780.x","volume":"67","author":"E van der Veer","year":"2012","unstructured":"van der Veer E, van der Goot W, de Monchy JGR, et al. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy. 2012;67(3):431\u20138.","journal-title":"Allergy"},{"issue":"5","key":"947_CR46","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11882-015-0525-1","volume":"15","author":"A Matito","year":"2015","unstructured":"Matito A, Carter M. Cutaneous and systemic mastocytosis in children: a risk factor for anaphylaxis? Curr Allergy Asthma Rep. 2015;15(5):22.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"23","key":"947_CR47","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","volume":"113","author":"KH Lim","year":"2009","unstructured":"Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113(23):5727\u201336.","journal-title":"Blood"},{"issue":"4","key":"947_CR48","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2165\/11588890-000000000-00000","volume":"12","author":"M Castells","year":"2011","unstructured":"Castells M, Metcalfe DD, Escribano L. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am J Clin Dermatol. 2011;12(4):259\u201370.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"947_CR49","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/j.ajpath.2011.01.020","volume":"178","author":"G Hoermann","year":"2011","unstructured":"Hoermann G, Cerny-Reiterer S, Perne A, et al. Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis. Am J Pathol. 2011;178(5):2344\u201356.","journal-title":"Am J Pathol"},{"issue":"6","key":"947_CR50","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1600-0625.1994.tb00291.x","volume":"3","author":"B Algermissen","year":"1994","unstructured":"Algermissen B, Bauer F, Schadendorf D, et al. Analysis of mast cell subpopulations (MCT, MCTC) in cutaneous inflammation using novel enzyme-histochemical staining techniques. Exp Dermatol. 1994;3(6):290\u20137.","journal-title":"Exp Dermatol"},{"issue":"11","key":"947_CR51","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/cup.14695","volume":"51","author":"C Mitteldorf","year":"2024","unstructured":"Mitteldorf C, Kulberg A, Tronnier M, et al. Subcellular expression of CD30 in cutaneous mastocytosis: an important factor for targeted treatment. J Cutan Pathol. 2024;51(11):881\u201392.","journal-title":"J Cutan Pathol"},{"issue":"10","key":"947_CR52","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1016\/j.jaip.2021.05.042","volume":"9","author":"V Deepak","year":"2021","unstructured":"Deepak V, Komarow HD, Alblaihess AA, et al. Expression of MRGPRX2 in skin mast cells of patients with maculopapular cutaneous mastocytosis. J Allergy Clin Immunol Pract. 2021;9(10):3841-3.e1.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"947_CR53","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/jcp.2004.017210","volume":"58","author":"AS Janssens","year":"2005","unstructured":"Janssens AS, Heide R, den Hollander JC, et al. Mast cell distribution in normal adult skin. J Clin Pathol. 2005;58(3):285\u20139.","journal-title":"J Clin Pathol"},{"issue":"1","key":"947_CR54","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/PAS.0b013e3180ca9a02","volume":"32","author":"TJ Hollmann","year":"2008","unstructured":"Hollmann TJ, Brenn T, Hornick JL. CD25 expression on cutaneous mast cells from adult patients presenting with urticaria pigmentosa is predictive of systemic mastocytosis. Am J Surg Pathol. 2008;32(1):139\u201345.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"947_CR55","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/his.14573","volume":"80","author":"P Drabent","year":"2022","unstructured":"Drabent P, Polivka L, Agopian J, et al. Establishing diagnostic criteria for mastocytosis in skin biopsies. Histopathology. 2022;80(3):501\u201314.","journal-title":"Histopathology"},{"issue":"2","key":"947_CR56","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/DAD.0000000000002878","volume":"47","author":"AL King","year":"2025","unstructured":"King AL, Montagnon CM, Todd A, et al. Quantifying mast cell and eosinophil cellular density in skin biopsy tissue from adults with maculopapular cutaneous mastocytosis as compared with urticaria and normal skin: a retrospective histopathologic study. Am J Dermatopathol. 2025;47(2):105\u20139.","journal-title":"Am J Dermatopathol"},{"issue":"8","key":"947_CR57","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1111\/jdv.18143","volume":"36","author":"J Gebhard","year":"2022","unstructured":"Gebhard J, Horny HP, Kristensen T, et al. Validation of dermatopathological criteria to diagnose cutaneous lesions of mastocytosis: importance of KIT D816V mutation analysis. J Eur Acad Dermatol Venereol. 2022;36(8):1367\u201375.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"947_CR58","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/modpathol.2013.117","volume":"27","author":"S Berezowska","year":"2014","unstructured":"Berezowska S, Flaig MJ, Rueff F, et al. Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis. Mod Pathol. 2014;27(1):19\u201329.","journal-title":"Mod Pathol"},{"issue":"6","key":"947_CR59","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/bjh.13231","volume":"168","author":"MC Carter","year":"2015","unstructured":"Carter MC, Metcalfe DD, Clark AS, et al. Abnormal bone marrow histopathology in paediatric mastocytosis. Br J Haematol. 2015;168(6):865\u201373.","journal-title":"Br J Haematol"},{"key":"947_CR60","unstructured":"Heymann WR. Telangiectasia macularis eruptiva perstans revisited. Dermatology world insights and inquiries. American Academy of Dermatology, 2016. Available from: https:\/\/www.aad.org\/dw\/dw-insights-and-inquiries\/medical-dermatology\/telangiectasia-macularis-eruptiva-perstans-revisited. [Accessed 14 Feb 2024]."},{"issue":"2","key":"947_CR61","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/bjd.20098","volume":"185","author":"F Jendoubi","year":"2021","unstructured":"Jendoubi F, Shourick J, Negretto M, et al. Cutaneous mastocytosis in adults with a serum tryptase level < 20 ng mL(-1): why we should investigate further. Br J Dermatol. 2021;185(2):453\u20135.","journal-title":"Br J Dermatol"},{"issue":"9","key":"947_CR62","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1182\/bloodadvances.2022007936","volume":"7","author":"J Chovanec","year":"2023","unstructured":"Chovanec J, Tunc I, Hughes J, et al. Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms. Blood Adv. 2023;7(9):1796\u2013810.","journal-title":"Blood Adv"},{"issue":"12","key":"947_CR63","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/ng.3696","volume":"48","author":"JJ Lyons","year":"2016","unstructured":"Lyons JJ, Yu X, Hughes JD, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. 2016;48(12):1564\u20139.","journal-title":"Nat Genet"},{"issue":"9","key":"947_CR64","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1016\/j.jaip.2021.12.031","volume":"10","author":"AM Waters","year":"2022","unstructured":"Waters AM, Park HJ, Weskamp AL, et al. Elevated basal serum tryptase: disease distribution and variability in a eregional health system. J Allergy Clin Immunol Pract. 2022;10(9):2424-35.e5.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"947_CR65","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","volume":"108","author":"AC Garcia-Montero","year":"2006","unstructured":"Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006;108(7):2366\u201372.","journal-title":"Blood"},{"issue":"23","key":"947_CR66","doi-asserted-by":"publisher","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","volume":"92","author":"H Nagata","year":"1995","unstructured":"Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A. 1995;92(23):10560\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"947_CR67","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1182\/bloodadvances.2023009826","volume":"7","author":"NA Boggs","year":"2023","unstructured":"Boggs NA, Sun X, Lyons JJ, et al. Challenges in applying diagnostic criteria for systemic mastocytosis. Blood Adv. 2023;7(13):3150\u20134.","journal-title":"Blood Adv"},{"issue":"10","key":"947_CR68","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1097\/01.pas.0000138181.89743.7b","volume":"28","author":"K Sotlar","year":"2004","unstructured":"Sotlar K, Horny HP, Simonitsch I, et al. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol. 2004;28(10):1319\u201325.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"947_CR69","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1373\/clinchem.2017.277897","volume":"64","author":"G Greiner","year":"2018","unstructured":"Greiner G, Gurbisz M, Ratzinger F, et al. Digital PCR: a sensitive and precise method for KIT D816V quantification in mastocytosis. Clin Chem. 2018;64(3):547\u201355.","journal-title":"Clin Chem"},{"key":"947_CR70","unstructured":"World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Vol. 2. Lyon: International Agency for Research on Cancer; 2017."},{"issue":"6","key":"947_CR71","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/bjd.14768","volume":"175","author":"S Guillen-Aguinaga","year":"2016","unstructured":"Guillen-Aguinaga S, Jauregui Presa I,\u00a0 Aguinaga-Ontoso E, et al. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. Br J Dermatol. 2016;175(6):1153\u201365.","journal-title":"Br J Dermatol"},{"issue":"5\u20136","key":"947_CR72","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/phpp.12248","volume":"32","author":"V Brazzelli","year":"2016","unstructured":"Brazzelli V, Grassi S, Merante S, et al. Narrow-band UVB phototherapy and psoralen-ultraviolet A photochemotherapy in the treatment of cutaneous mastocytosis: a study in 20 patients. Photodermatol Photoimmunol Photomed. 2016;32(5\u20136):238\u201346.","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"6","key":"947_CR73","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/j.1365-2133.1978.tb03592.x","volume":"98","author":"E Christophers","year":"1978","unstructured":"Christophers E, Honigsmann H, Wolff K, et al. PUVA-treatment of urticaria pigmentosa. Br J Dermatol. 1978;98(6):701\u20132.","journal-title":"Br J Dermatol"},{"issue":"1","key":"947_CR74","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000245681","volume":"195","author":"O Godt","year":"1997","unstructured":"Godt O, Procksch E, Streit V, et al. Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis. Dermatology. 1997;195(1):35\u20139.","journal-title":"Dermatology"},{"issue":"6","key":"947_CR75","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1159\/000504842","volume":"236","author":"M Distler","year":"2020","unstructured":"Distler M, Maul JT, Steiner UC, et al. Efficacy of omalizumab in mastocytosis: allusive indication obtained from a prospective, double-blind, multicenter study (XOLMA study). Dermatology. 2020;236(6):529\u201339.","journal-title":"Dermatology"},{"issue":"6","key":"947_CR76","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/cea.13592","volume":"50","author":"F Jendoubi","year":"2020","unstructured":"Jendoubi F, Gaudenzio N, Gallini A, et al. Omalizumab in the treatment of adult patients with mastocytosis: a systematic review. Clin Exp Allergy. 2020;50(6):654\u201361.","journal-title":"Clin Exp Allergy"},{"issue":"7","key":"947_CR77","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1016\/j.jaip.2023.04.008","volume":"11","author":"JS McComish","year":"2023","unstructured":"McComish JS, Slade CA, Buizen L, et al. Randomized controlled trial of omalizumab in treatment-resistant systemic and cutaneous mastocytosis (ROAM). J Allergy Clin Immunol Pract. 2023;11(7):2248-50.e3.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"947_CR78","unstructured":"American Initiative in Mast Cell Diseases, Centers of Excellence. 2024. Available from: https:\/\/aimcd.net\/centers\/. [Accessed 16 Sep 2024]."},{"issue":"6","key":"947_CR79","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/j.jaci.2015.04.024","volume":"136","author":"MC Carter","year":"2015","unstructured":"Carter MC, Clayton ST, Komarow HD, et al. Assessment of clinical findings, tryptase levels, and bone marrow histopathology in the management of pediatric mastocytosis. J Allergy Clin Immunol. 2015;136(6):1673-9.e3.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"947_CR80","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.anai.2021.06.019","volume":"127","author":"JJ Lyons","year":"2021","unstructured":"Lyons JJ. Inherited and acquired determinants of serum tryptase levels in humans. Ann Allergy Asthma Immunol. 2021;127(4):420\u20136.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"947_CR81","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.jaip.2020.12.022","volume":"9","author":"D Fuchs","year":"2021","unstructured":"Fuchs D, Kilbertus A, Kofler K, et al. Scoring the risk of having systemic mastocytosis in adult patients with mastocytosis in the skin. J Allergy Clin Immunol Pract. 2021;9(4):1705-12.e4.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"947_CR82","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2340\/00015555-3504","volume":"100","author":"J Czarny","year":"2020","unstructured":"Czarny J, Zuk M, Zawrocki A, et al. New approach to paediatric mastocytosis: implications of KIT D816V mutation detection in peripheral blood. Acta Derm Venereol. 2020;100(10):149.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"947_CR83","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1182\/hematology.2022000366","volume":"2022","author":"C Akin","year":"2022","unstructured":"Akin C. How to evaluate the patient with a suspected mast cell disorder and how\/when to manage symptoms. Hematol Am Soc Hematol Educ Progr. 2022;2022(1):55\u201363.","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"issue":"5","key":"947_CR84","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/eci.12607","volume":"46","author":"M Jawhar","year":"2016","unstructured":"Jawhar M, Schwaab J, Horny HP, et al. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. Eur J Clin Invest. 2016;46(5):392\u20137.","journal-title":"Eur J Clin Invest"},{"issue":"4","key":"947_CR85","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1182\/blood.2023023347","volume":"144","author":"JC McMurray","year":"2024","unstructured":"McMurray JC, Pachecho CS, Schornack BJ, et al. Standardized indolent systemic mastocytosis evaluations across a healthcare system: implications for screening accuracy. Blood. 2024;144(4):408\u201319.","journal-title":"Blood"},{"key":"947_CR86","unstructured":"American Initiative in Mast Cell Diseases, AIM Network. 2024. Available from: https:\/\/aimcd.net\/centers\/. [Accessed 19 Mar 2024]."},{"issue":"8","key":"947_CR87","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","volume":"103","author":"C Akin","year":"2004","unstructured":"Akin C, Fumo G, Yavuz AS, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood. 2004;103(8):3222\u20135.","journal-title":"Blood"},{"issue":"1","key":"947_CR88","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jaci.2004.04.046","volume":"114","author":"C Akin","year":"2004","unstructured":"Akin C, Metcalfe DD. The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol. 2004;114(1):13\u20139.","journal-title":"J Allergy Clin Immunol"},{"issue":"40","key":"947_CR89","doi-asserted-by":"publisher","first-page":"68950","DOI":"10.18632\/oncotarget.10711","volume":"8","author":"I Alvarez-Twose","year":"2017","unstructured":"Alvarez-Twose I, Matito A, Morgado JM, et al. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. Oncotarget. 2017;8(40):68950\u201363.","journal-title":"Oncotarget"},{"issue":"10","key":"947_CR90","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.leukres.2014.07.010","volume":"38","author":"CP de Melo","year":"2014","unstructured":"de Melo CP, Machado-Neto JA, Scopim-Ribeiro R, et al. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. Leuk Res. 2014;38(10):1245\u201351.","journal-title":"Leuk Res"},{"issue":"41","key":"947_CR91","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004934","volume":"95","author":"L Huang","year":"2016","unstructured":"Huang L, Wang SA, Konoplev S, et al. Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: a case report. Medicine (Baltimore). 2016;95(41): e4934.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"947_CR92","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.leukres.2005.08.015","volume":"30","author":"LY Zhang","year":"2006","unstructured":"Zhang LY, Smith ML, Schultheis B, et al. A novel K509I mutation of KIT identified in familial mastocytosis: in vitro and in vivo responsiveness to imatinib therapy. Leuk Res. 2006;30(4):373\u20138.","journal-title":"Leuk Res"},{"issue":"2","key":"947_CR93","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/leu.2017.234","volume":"32","author":"DJ DeAngelo","year":"2018","unstructured":"DeAngelo DJ, George TI, Linder A, et al. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. 2018;32(2):470\u20138.","journal-title":"Leukemia"},{"issue":"26","key":"947_CR94","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","volume":"374","author":"J Gotlib","year":"2016","unstructured":"Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374(26):2530\u201341.","journal-title":"N Engl J Med"},{"issue":"3","key":"947_CR95","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jaci.2018.06.003","volume":"142","author":"B van Anrooij","year":"2018","unstructured":"van Anrooij B, Oude Elberink JNG, Span LFR, et al. Midostaurin in patients with indolent systemic mastocytosis: an open-label phase 2 trial. J Allergy Clin Immunol. 2018;142(3):1006-8.e7.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"947_CR96","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","volume":"27","author":"DJ DeAngelo","year":"2021","unstructured":"DeAngelo DJ, Radia DH, George TI, et al. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med. 2021;27(12):2183\u201391.","journal-title":"Nat Med"},{"issue":"6","key":"947_CR97","doi-asserted-by":"publisher","first-page":"2200339","DOI":"10.1056\/EVIDoa2200339","volume":"2","author":"J Gotlib","year":"2023","unstructured":"Gotlib J, Castells M, Elberink HO, et al. Avapritinib versus placebo in indolent systemic mastocytosis. NEJM Evid. 2023;2(6):2200339.","journal-title":"NEJM Evid."},{"issue":"12","key":"947_CR98","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","volume":"27","author":"J Gotlib","year":"2021","unstructured":"Gotlib J, Reiter A, Radia DH, et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nat Med. 2021;27(12):2192\u20139.","journal-title":"Nat Med"},{"issue":"8","key":"947_CR99","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1038\/s41375-022-01615-z","volume":"36","author":"A Reiter","year":"2022","unstructured":"Reiter A, Gotlib J, Alvarez-Twose I, et al. Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis. Leukemia. 2022;36(8):2108\u201320.","journal-title":"Leukemia"},{"issue":"21","key":"947_CR100","doi-asserted-by":"publisher","first-page":"5750","DOI":"10.1182\/bloodadvances.2022007539","volume":"6","author":"A Reiter","year":"2022","unstructured":"Reiter A, Schwaab J, DeAngelo DJ, et al. Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis. Blood Adv. 2022;6(21):5750\u201362.","journal-title":"Blood Adv"},{"key":"947_CR101","doi-asserted-by":"crossref","unstructured":"Gotlib J, Castells M, Elberink HO, et al. Reductions in indolent systemic mastocytosis biomarker burden with avapritinib in the registrational, double-blind placebo-controlled PIONEER trial. Presented at: European Hematology Association Annual Meeting; June 8-15, 2023; Frankfurt, and virtual. Poster 1017.","DOI":"10.1097\/01.HS9.0000970972.77960.03"},{"key":"947_CR102","unstructured":"Maurer M, Siebenhaar F, Broesby-Olsen S, et al. Avapritinib improved skin findings in patients with indolent systemic mastocytosis (ISM) in the registrational, double-blind, placebo-controlled PIONEER study. Presented at: 2023 AAAAI Annual Meeting; February 24-27, 2023; San Antonio (TX). Abstract L69."},{"key":"947_CR103","unstructured":"ClinicalTrials.gov. 2024. Available from: https:\/\/www.clinicaltrials.gov\/. [Accessed 28 Oct 2024]."}],"updated-by":[{"DOI":"10.1007\/s40257-025-00972-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000}}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00947-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00947-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00947-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T17:27:09Z","timestamp":1757179629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00947-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":103,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["947"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00947-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40257-025-00972-6","asserted-by":"object"}]},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"7 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40257-025-00972-6","URL":"https:\/\/doi.org\/10.1007\/s40257-025-00972-6","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Blueprint Medicines Corporation provided funding for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lauren M. Madigan served on an international advisory board for Blueprint Medicines and participated as a speaker in a non-Continuing Medical Education (CME) session on recognizing and diagnosis mastocytosis; Section editor, JAMA Dermatology. Nathan A. Boggs participated in a Blueprint Medicines-sponsored patient advocacy summit; participated in developing a Blueprint-sponsored webinar for the College of American Pathologists. Anton V. Rets participated in developing a Blueprint Medicines-sponsored webinar for the College of American Pathologists. Alejandro A. Gru is an investigator for Innate Pharma, Stemline Therapeutics, and Dren Bio; a consultant for Blueprint Medicines; and a speaker for Kyowa Kirin. Tsewang Tashi is a member of the advisory board and a primary investigator in Blueprint Medicines clinical trials, Cogent Biosciences, and PharmaEssentia; a member of the study steering committee for Blueprint Medicines clinical trials. David. A Wada and Melody C. Carter have no conflicts of interest that are directly relevant to the content of this article. Scott R. Florell is a consultant for Orlucent Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Patients or their representatives provided consent for the publication of any identifiable photographs.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the concept, research, and writing of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}